Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099294 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00099294 is a Phase 3 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 300 participants.
The verdict
NCT00099294, a Phase 3 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with best supportive care.
Interventions
- DRUG Glufosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099294
The ClinicalTrials.gov registry entry for NCT00099294 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glufosfamide is the first listed.
NCT00099294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099294 about?
NCT00099294 is a clinical study titled "Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer". The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with best supportive care.
What is the current status of trial NCT00099294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00099294?
The interventions under investigation include: Glufosfamide (DRUG).
Who is sponsoring clinical trial NCT00099294?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.